Advertisement
KRRO vs MGNX
Which Stock Would AI Choose? Korro Bio (KRRO) vs. MacroGenics (MGNX) Stock Comparison
Key Takeaways
- KRRO is a clinical-stage genetic-medicine company focused on RNA (ribonucleic acid) editing, while MGNX develops antibody-based cancer therapeutics.
- Korro Bio reset its pipeline after a late-2025 clinical setback and is now advancing a new lead program, KRRO-121, with cash runway into the second half of 2028.
- MacroGenics generates meaningful revenue through pharma partnerships (Sanofi, Incyte, and Gilead) but faces a partial FDA clinical hold on one study.
- Analyst consensus is broadly constructive on both names, though price targets sit well above recent trading levels for each stock.
- Relative performance diverged sharply in 2026, with MGNX outpacing the broader medical sector while KRRO traded below key longer-term moving averages.
Introduction
Investors screening small- and mid-cap biotechnology often encounter two very different risk profiles wearing the same label: clinical-stage drug developers. KRRO (Korro Bio, Inc.) and MGNX (MacroGenics, Inc.) both sit in the biopharmaceutical space, yet they pursue distinct scientific approaches, funding models, and catalysts. This stock comparison examines how the two companies differ in business model, recent market activity, and risk exposure, and how their relative performance and market positioning have evolved. The analysis is relevant for traders tracking sector momentum as well as longer-horizon investors evaluating pre-revenue pipeline companies against partnered, revenue-generating developers.
KRRO Overview and Recent Performance
Korro Bio, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines based on RNA editing, a technique designed to make precise, transient single-base edits to RNA rather than permanently altering DNA (deoxyribonucleic acid). The company's first development candidate, KRRO-110, was aimed at Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause lung and liver disease. In late 2025, Korro disclosed negative results from its Phase 1/2a REWRITE trial and subsequently amended its research agreement with Novo Nordisk, a setback that weighed heavily on sentiment and contributed to a significant decline in the share price over the trailing twelve months.
In recent weeks, however, the company has shifted attention to a new lead asset, KRRO-121, an RNA-editing candidate being developed for hyperammonemia (elevated ammonia in the blood) in patients with urea cycle disorders and hepatic encephalopathy, a brain condition linked to liver dysfunction. Korro reported a cash position of roughly $85.2 million as of December 31, 2025, which management expects to fund operations into the second half of 2028. Collaboration revenue rose to about $6.4 million in 2025, and several analysts upgraded the stock in early 2026, citing the refreshed pipeline and financing position.
MGNX Overview and Recent Performance
MacroGenics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops monoclonal antibody-based therapeutics, primarily for cancer. The company's proprietary platforms include DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, and it has advanced an ADC (antibody-drug conjugate) pipeline. Unlike Korro, MacroGenics has generated substantial revenue from partnerships and commercial milestones tied to products such as Zynyz (retifanlimab), partnered with Incyte, and TZIELD (teplizumab), partnered with Sanofi; full-year 2025 revenue was approximately $149.5 million.
Recent market activity has been volatile. MacroGenics shares rallied strongly in early 2026 and significantly outperformed the broader medical sector on a year-to-date basis. At the same time, the company announced that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational bispecific molecule targeting PD-1 and CTLA-4, in gynecologic cancers, following safety events that included one fatal outcome. Analysts have nevertheless raised price targets in recent months, pointing to the ADC pipeline, partnerships, and a strengthened cash position.
Trending AI Robots
For traders who prefer a systematic, data-driven approach to navigating fast-moving names like KRRO and MGNX, Tickeron's Trending AI Robots page offers a curated view of automated strategies. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistical profile. Because market conditions change constantly, only the best and most suitable bots for the current environment earn a place in the Trending AI Robots section, which highlights strategies currently showing strength rather than a static list of past performers. Browsing the page can help investors compare approaches side by side and identify bots aligned with their own objectives and risk tolerance.
Head-to-Head Comparison
The clearest contrast between the two companies is their stage of commercial development and their financing models. KRRO is effectively pre-revenue, relying on collaboration income and equity financing to fund an early-stage, unproven RNA-editing platform. Its recent pipeline reset introduces meaningful execution risk, but the company also holds a cash runway extending into 2028 and has attracted multiple analyst upgrades in recent months. Its share price remains below longer-term moving averages, indicating that short-term strength has not yet repaired the longer-term downtrend.
MGNX, by contrast, benefits from recurring partnership and milestone revenue and a diversified oncology portfolio across multiple pharma collaborations. That structure reduces dependence on any single program, but the partial clinical hold on the LINNET study highlights the clinical and regulatory risks inherent to its pipeline. On momentum, MGNX has shown stronger relative performance in 2026, while KRRO has been the more contrarian setup. Sector exposure differs as well: Korro operates in genetic medicine, a capital-intensive field with long development timelines, whereas MacroGenics competes in the crowded antibody and ADC oncology market, where deal activity can rapidly shift valuation expectations.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor MGNX in the current environment. MacroGenics has demonstrated stronger recent momentum and relative performance, backed by a more durable revenue and partnership structure and a series of upcoming clinical readouts. Korro Bio offers a higher-beta, catalyst-driven profile with a longer cash runway, but its trend has been less consistent following the late-2025 pipeline setback. This assessment reflects probabilistic, model-driven positioning rather than a definitive forecast, and it may shift as new clinical data, regulatory decisions, or financing events emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRRO is a Hold and MGNX is a Hold.
KRRO's RSI Indicator climbs out of oversold territory
The RSI Oscillator for KRRO moved out of oversold territory on September 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 31 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 228 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
KRRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRRO as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for KRRO turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 36 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
KRRO moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KRRO crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KRRO entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.347) is normal, around the industry mean (2.978). P/E Ratio (-0.955) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MGNX in downward trend: price dove below 50-day moving average on September 29, 2026
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 78 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.185) is normal, around the industry mean (3.009). P/E Ratio (-15.864) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KRRO | MGNX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 50 | 57 | |
P/E GROWTH RATING 1..100 | 20 | 21 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KRRO's Valuation (58) in the null industry is in the same range as MGNX (88) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
KRRO's Profit vs Risk Rating (100) in the null industry is in the same range as MGNX (100) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's SMR Rating (97) in the Biotechnology industry is in the same range as KRRO (100) in the null industry. This means that MGNX’s stock grew similarly to KRRO’s over the last 12 months.
KRRO's Price Growth Rating (50) in the null industry is in the same range as MGNX (57) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
KRRO's P/E Growth Rating (20) in the null industry is in the same range as MGNX (21) in the Biotechnology industry. This means that KRRO’s stock grew similarly to MGNX’s over the last 12 months.
| KRRO | MGNX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 1 day ago 84% |
| Momentum ODDS (%) | 2 days ago 90% | 1 day ago 86% |
| MACD ODDS (%) | 2 days ago 88% | N/A |
| TrendWeek ODDS (%) | 2 days ago 90% | 1 day ago 86% |
| TrendMonth ODDS (%) | 2 days ago 89% | 1 day ago 87% |
| Advances ODDS (%) | 6 days ago 86% | 1 day ago 85% |
| Declines ODDS (%) | 8 days ago 90% | 7 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 84% | 1 day ago 88% |
| Aroon ODDS (%) | 2 days ago 86% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KRRO’s FA Score shows that 1 FA rating(s) are green while MGNX’s FA Score has 1 green FA rating(s).
- KRRO’s FA Score: 1 green, 4 red.
- MGNX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KRRO’s TA Score shows that 4 TA indicator(s) are bullish while MGNX’s TA Score has 3 bullish TA indicator(s).
- KRRO’s TA Score: 4 bullish, 7 bearish.
- MGNX’s TA Score: 3 bullish, 5 bearish.
Price Growth
KRRO (@Biotechnology) experienced а +7.15% price change this week, while MGNX (@Biotechnology) price change was +2.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Reported Earning Dates
KRRO is expected to report earnings on Nov 18, 2026.
MGNX is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DFSE | 46.33 | 0.13 | +0.28% |
| Dimensional Emerging Markets Sustainability Core 1 ETF (DFSE) | |||
| IBCB | 23.83 | 0.06 | +0.25% |
| iShares iBonds Dec 2036 Term Corporate ETF (IBCB) | |||
| ARCM | 100.07 | N/A | N/A |
| Arrow Reserve Capital Management ETF (ARCM) | |||
| VOX | 188.96 | -0.05 | -0.03% |
| Vanguard Communication Services ETF (VOX) | |||
| GEVG | 18.76 | -0.82 | -4.17% |
| Leverage Shares 2X Long GEV Daily ETF (GEVG) | |||
KRRO and
Correlation & Price change
A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with MGNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then MGNX could also see price increases.
| Ticker / NAME | Correlation To KRRO | 1D Price Change % | ||
|---|---|---|---|---|
| KRRO | 100% | +5.95% | ||
| MGNX - KRRO | 45% Loosely correlated | +4.80% | ||
| TRDA - KRRO | 43% Loosely correlated | +3.53% | ||
| RLAY - KRRO | 42% Loosely correlated | +7.96% | ||
| AVIR - KRRO | 38% Loosely correlated | +1.71% | ||
| NRIX - KRRO | 37% Loosely correlated | +4.69% | ||
More | ||||